Zacks Research cut shares of DaVita (NYSE:DVA – Free Report) from a strong-buy rating to a hold rating in a research report released on Monday,Zacks.com reports.
A number of other equities research analysts have also issued reports on the stock. TD Cowen raised their price target on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a report on Monday, May 11th. Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a report on Monday, June 8th. Truist Financial increased their price target on shares of DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research note on Friday, May 8th. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and lifted their price objective for the company from $126.00 to $220.00 in a research report on Wednesday, May 6th. Finally, UBS Group lifted their price target on DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $199.17.
DaVita Trading Down 0.6%
DaVita (NYSE:DVA – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The business had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.36 billion. During the same period in the prior year, the firm earned $2.00 earnings per share. The company’s revenue was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Research analysts predict that DaVita will post 15.07 earnings per share for the current year.
Insider Buying and Selling
In related news, insider Kathleen Alyce Waters sold 15,405 shares of DaVita stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the transaction, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at $25,440,571.40. The trade was a 27.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.50% of the stock is owned by insiders.
Institutional Investors Weigh In On DaVita
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership grew its holdings in DaVita by 114.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after buying an additional 636,191 shares in the last quarter. Norges Bank bought a new stake in shares of DaVita in the fourth quarter worth about $49,164,000. Corient Private Wealth LLC grew its holdings in DaVita by 1,493.1% during the 4th quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock valued at $40,706,000 after buying an additional 335,809 shares in the last quarter. Man Group plc grew its holdings in shares of DaVita by 1,608.6% in the second quarter. Man Group plc now owns 285,809 shares of the company’s stock valued at $40,713,000 after purchasing an additional 269,081 shares in the last quarter. Finally, Voloridge Investment Management LLC increased its holdings in shares of DaVita by 2,905.7% in the 3rd quarter. Voloridge Investment Management LLC now owns 228,221 shares of the company’s stock worth $30,324,000 after buying an additional 220,628 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.
DaVita Company Profile
DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.
Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.
Read More
- Five stocks we like better than DaVita
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
